MDCX Company Profile and Key Details

MDCX has shown weak momentum, losing -6.16% over the past week and -41.95% over the past quarter, though year-to-date performance is down -10.46%. Short-term trend indicators are bullishly aligned (SMA20 19.6%, SMA50 0.4%, SMA200 -43.72%). The stock’s 14-day RSI is 59.18 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -84.79% below its high and over 48.25% above its low. Average 10-day trading volume of 2.88 million shares is significantly above the 3-month average of 679.40 thousand, indicating heightened recent market interest.

Medicus Pharma Ltd. Common Stock has 18.72 million shares outstanding. The public float is 9.21 million shares, elevated short interest at 3.01% of float. This equals 345.96 thousand shares. The short ratio is 1.04 days. Institutional investors hold 23.25% of the float. Insiders own 35.9%.

Wall Street analysts project EPS growth of 11.71% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $27.00. The high target offers 6823.08% upside. The low target suggests 6823.08% downside. The mean target is $27.00. This offers 6823.08% upside. Medicus Pharma Ltd. Common Stock earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 14, 2025, missed forecasts by 71.05%. The prior quarter beat by 10.26%. Over the last six quarters, Apple has recorded several small beats. These include 126.67% in August 22, 2024.

Medicus Pharma Ltd. Common Stock (NASDAQ:MDCX) shares are down -10.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Medicus Pharma Ltd. Common Stock trading at a premium to the broader market with a P/E of -0.27. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $25.79, suggesting 6558.92% upside. Our AI forecast model points to short-term strength (75.57% over two weeks), a medium-term rise (67.83% over three months), and a longer-term loss (-38.03% over one year), with expected trading ranges indicating moderate volatility.

Medicus Pharma Ltd. Common Stock (NASDAQ:MDCX) closed at $0.39 USD, losing -$0.29 (-42.87%) from the previous close of $0.68. The stock is currently within 5% of its 52-week low $0.37 and $8.94. With a market capitalization of about $9.57 million, Medicus Pharma Ltd. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~-2.00). Key stats such as the average daily volume over the past year has been around 819.86 thousand shares, trading with heavier-than-usual volume. Headquartered in W. Conshohocken, None, Medicus Pharma Ltd. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Raza Bokhari, the company employs approximately 12 people and listed since November 15, 2024. Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

Our AI price prediction model suggests that Medicus Pharma Ltd. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 75.57%, with price expected at $0.68 by March 20, 2026, within a range of $0.60 to $0.76 3-Month Outlook: Projected rise of 67.83%, reaching $0.65 by June 01, 2026, with a range of $0.36 to $0.77. 1-Year Outlook: Projected loss of -38.03%, with price at $0.24 by March 05, 2027, within a range of $0.00 to $0.00.

Medicus Pharma Ltd. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.40. This means the shares are trading near this model’s fair value.

Medicus Pharma Ltd. Common Stock trades at a P/E ratio of -0.27, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -8.74 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.55, also below market averages.